METASTOP FITOELIT

Instructions for veterinary use
medicinal product PHYTOELITA METASTOP for dogs and cats

General information
1. Trade name of the medicinal product: PHYTOELITA® METASTOP.
International nonproprietary name: not assigned. Group name: drug of plant origin.

2. Dosage form: tablets for oral use.

The medicinal product PHYTOELITA® METASTOP contains as an active substance a phytocomplex - 3.5%, which is an aqueous extract from plant materials and mushrooms: shiitake, reishi, broccoli seeds, chaga, oregano, horsetail herb, agrimony herb, shepherd's purse common grass, immortelle sandy flowers, bedstraw grass, greater celandine grass, stinging nettle leaves, birch leaves, fireweed angustifolia (fireweed) grass, St. John's wort grass, purple coneflower, comfrey root, meadowsweet flowers, lemon balm herb , burdock roots, red clover flowers, licorice roots, calendula officinalis flowers, burnet rhizomes and roots, and as excipients: lactose, potato starch, calcium stearate.

The content of amine nitrogen in one tablet is not less than 5×10–7 g.

3. The drug is a biconvex tablet weighing 0.2 g from white to light yellow. Inclusions and slight marbling are allowed.

The shelf life of the medicinal product, subject to storage conditions, is 12 months from the date of issue. It is prohibited to use the medicinal product PHYTOELITA® METASTOP after the expiration date.

4. The drug is released packaged in 50 tablets in polymer jars complete with lids. Each jar, along with instructions for use, is placed in a box made of cardboard.

5. PHYTOELITA® METASTOP is stored in the manufacturer’s sealed packaging, separate from food and feed, in a place protected from direct sunlight at a temperature not exceeding 25 °C.

6. PHYTOELITE® METASTOP should be stored out of the reach of children.

7. Unused medicinal product is disposed of in accordance with legal requirements.

8. Dispensing conditions: without a veterinarian's prescription.

Pharmacological (biological) properties

.9. The drug PHYTOELITA® METASTOP belongs to antitumor drugs of plant origin in combinations.

10. The mechanism of action of the drug is determined by the phytotherapeutic activity of biologically active substances of extracts from plant raw materials.

Polysaccharides contained in shiitake mushrooms, including lentinan (C6H10O3)n, exhibit antitumor and antimetastatic activity.

The carcinostatic effect of lentinan is mainly the result of activation of perforin production. D-glucan binds to the surface layer of the lymphocyte or to a specific serum protein, which activates macrophages, T cells, NK cells and other effector cells. This leads to increased production of antibodies, interleukins (IL-1 and IL-2) and interferon (IFN). Polysaccharide KS-2 also has antitumor properties due to the induction of interferon and stimulation of T-lymphocytes. The lanophil polysaccharide contained in reishi mushrooms prevents the growth and metastasis of a wide range of tumors by activating macrophages and T-lymphocytes and stimulating the production of interferon. Pterins contained in chaga have a cytostatic effect and delay the initial stages of the tumor process. The lignan aglycone arctigenin (the active substance of burdock) has direct antitumor activity. Indoles (diindolylmethane) in broccoli prevent the formation of carcinogenic estrogen. Hanerol fireweed has a broad antitumor effect, including breast cancer.

The glycoside trifolysin contained in clover has a pronounced antimetastatic effect by reducing the rate of capillary growth.

The medicinal product PHYTOELITA® METASTOP is classified as a low-hazard substance in terms of the degree of impact on the body (hazard class 4 according to GOST 12.1.007-76). The drug does not have cumulative, embryotoxic or teratogenic properties.

Application procedure

11. PHYTOELITA® METASTOP is used in cats and dogs as an antimetastatic, antitoxic, antitumor and adaptogenic agent in the preoperative and postoperative periods, as well as for the purpose of detoxifying the body during neoplasms.

12. A contraindication to the use of the drug is individual hypersensitivity to the components of the drug.

13. People with hypersensitivity to the components of the drug PHYTOELITA® METASTOP should avoid direct contact with the drug. When working with the drug PHYTOELITA® METASTOP, you should follow the general rules of personal hygiene and safety precautions provided for when working with medicinal products 

reparations. Empty medicine cans must not be used for household purposes; they must be disposed of with household waste. If allergic reactions occur or if the drug accidentally enters the human body, you should immediately contact a medical facility (bring with you the instructions for use of the drug or the label).

14. The drug can be used by pregnant animals and animals during lactation. There are no specific features for using the drug.

15. The drug is administered to animals individually orally in the following doses:
- in the preoperative period, 3 days before surgery - for dogs, 1 tablet per 10 kg of body weight, for cats, 1 tablet per animal 3 times a day;
- in the postoperative period throughout the life of the animal, every 3 months in courses of 7 days - for dogs, 1 tablet per 10 kg of body weight, for cats, 1 tablet per animal 3 times a day.

16. There are no side effects or complications when using the drug PHYTOELITA® METASTOP in accordance with the instructions. In rare cases, after using the drug, the animal experiences chills, trembling, and fever. These reactions are physiologically adequate to the effects of the drug and do not require discontinuation of the drug.

17. No overdose symptoms were identified. In case of increased individual sensitivity of the animal to the components of the drug and the appearance of adverse reactions, the use of the drug is stopped and desensitizing or symptomatic therapy is carried out.

18. There is no information about the incompatibility of the medicinal product PHYTOELITA® METASTOP with other medicinal products and (or) feed.

19. The specific effects of the drug upon first administration or upon its withdrawal have not been established.

20. If one or more doses of the drug are missed, treatment should be resumed as soon as possible in the prescribed dosage and regimen.

21. The drug is not intended for use in productive animals.